Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Can a simple blood test predict brain damage from childhood cancer treatment?

NCT ID NCT07381959

Knowledge-focused Sponsor: Uppsala University Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This observational study aims to find blood markers that show brain injury caused by cancer treatments in children with brain tumors. Researchers will collect plasma samples from 560 children before and after surgery, during radiation or chemotherapy, and up to three years later. They will compare results with healthy children to identify treatment-specific biomarkers that could guide safer therapies.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

What this could lead to
If successful, this study could identify blood tests that detect brain injury early, helping doctors tailor treatments to reduce long-term harm in children.
What could go wrong
This is an early observational study, not a treatment trial. It may not find clear biomarkers, and results may not apply to all children or hospitals.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

About 560 people

The number the study aims to enrol. It can still change while the study runs.

Started

Aug 2021

Expected to finish

Dec 2031

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

Groups A and B will be selected from all children, 0-17 years of age, in Sweden with primary (newly diagnosed) brain tumors. Group C will be selected from: * Healthy sibling controls to other study participants, OR * Siblings to other children admitted to Uppsala University Hospital, OR * Other healthy children for example those who attend Uppsala University Hospital for another reason (e.g., minor elective daycare surgery).

Ages

Up to 17 years

Sex

Anyone

Healthy volunteers

Accepted

You do not need to have the condition being studied to take part.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria, Group A (treated with radiation): * Age 0-17 years old, AND * Diagnosed with primary brain tumor through surgery, biopsy, or other diagnostic method (e.g., for germinoma) at Uppsala University Hospital or at another university hospital in Sweden, AND * Referred for radiotherapy at Skandion Clinic in Uppsala and/or at their local hospital (in some cases), with/without the addition of other cancer treatments. Inclusion Criteria, Group B (treated without radiation/radiation naive): * Age 0-17 years old, AND * Diagnosed with primary brain tumor through surgery, biopsy, or other diagnostic method (e.g., for optic pathway glioma in neurofibromatosis type 1 and germinoma) at Uppsala University Hospital or at another university hospital in Sweden, AND * Not referred to radiotherapy and treated with/without the addition of other cancer treatments. Inclusion Criteria, Group C (healthy control group): * Age 0-17 years old at time of recruitment Exclusion Criteria, Groups A + B: * Diagnosed with a tumor only in the spinal cord (solitary spinal tumor). * Diagnosed with a tumor considered palliative already at diagnosis (e.g., diffuse intrinsic pontine glioma) Exclusion Criteria, Group C: * Have diagnosis of chronic disease that requires continuous medication. Exclusion Criteria, all groups: * Unable to provide informed consent due to language difficulties.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Brain tumor are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

brain cancer brain neoplasm childhood malignant neoplasm neoplasm primary brain neoplasm

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Brain tumor Childhood brain tumor Childhood cancer

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    1 site. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Uppsala University

    RECRUITING

    Uppsala, Sweden

More trials for these conditions

Other studies related to the condition(s) this trial covers.